173 related articles for article (PubMed ID: 20217604)
21. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
Mai J; Song S; Rui M; Liu D; Ding Q; Peng J; Xu Y
J Control Release; 2009 Nov; 139(3):174-81. PubMed ID: 19576253
[TBL] [Abstract][Full Text] [Related]
22. Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles.
Wang M; Löwik DW; Miller AD; Thanou M
Bioconjug Chem; 2009 Jan; 20(1):32-40. PubMed ID: 19099499
[TBL] [Abstract][Full Text] [Related]
23. Preparation and in vitro targeting of sterically stabilized liposomes modified with chimeric TNT-3 monoclonal antibody.
Pan H; Niu GQ; Pan J; Lu WY
Yao Xue Xue Bao; 2006 Jun; 41(6):506-12. PubMed ID: 16927823
[TBL] [Abstract][Full Text] [Related]
24. Selection of tumor-specific internalizing human antibodies from phage libraries.
Poul MA; Becerril B; Nielsen UB; Morisson P; Marks JD
J Mol Biol; 2000 Sep; 301(5):1149-61. PubMed ID: 10966812
[TBL] [Abstract][Full Text] [Related]
25. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105).
Völkel T; Hölig P; Merdan T; Müller R; Kontermann RE
Biochim Biophys Acta; 2004 May; 1663(1-2):158-66. PubMed ID: 15157618
[TBL] [Abstract][Full Text] [Related]
26. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
27. Polymeric nanoparticles for drug delivery.
Chan JM; Valencia PM; Zhang L; Langer R; Farokhzad OC
Methods Mol Biol; 2010; 624():163-75. PubMed ID: 20217595
[TBL] [Abstract][Full Text] [Related]
28. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).
Maruyama K; Ishida O; Kasaoka S; Takizawa T; Utoguchi N; Shinohara A; Chiba M; Kobayashi H; Eriguchi M; Yanagie H
J Control Release; 2004 Aug; 98(2):195-207. PubMed ID: 15262412
[TBL] [Abstract][Full Text] [Related]
29. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
30. Polymeric micelles: polyethylene glycol-phosphatidylethanolamine (PEG-PE)-based micelles as an example.
Sawant RR; Torchilin VP
Methods Mol Biol; 2010; 624():131-49. PubMed ID: 20217593
[TBL] [Abstract][Full Text] [Related]
31. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat.
Huwyler J; Yang J; Pardridge WM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1541-6. PubMed ID: 9316870
[TBL] [Abstract][Full Text] [Related]
32. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
33. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
34. A modified protocol for efficient DNA encapsulation into pegylated immunoliposomes (PILs).
Skjørringe T; Gjetting T; Jensen TG
J Control Release; 2009 Oct; 139(2):140-5. PubMed ID: 19545595
[TBL] [Abstract][Full Text] [Related]
35. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles.
Schroeder JE; Shweky I; Shmeeda H; Banin U; Gabizon A
J Control Release; 2007 Dec; 124(1-2):28-34. PubMed ID: 17928088
[TBL] [Abstract][Full Text] [Related]
36. Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer.
Kamps JA; Koning GA; Velinova MJ; Morselt HW; Wilkens M; Gorter A; Donga J; Scherphof GL
J Drug Target; 2000; 8(4):235-45. PubMed ID: 11144234
[TBL] [Abstract][Full Text] [Related]
37. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
38. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
Hong M; Zhu S; Jiang Y; Tang G; Pei Y
J Control Release; 2009 Jan; 133(2):96-102. PubMed ID: 18840485
[TBL] [Abstract][Full Text] [Related]
39. Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells.
Xiong XB; Mahmud A; Uludağ H; Lavasanifar A
Biomacromolecules; 2007 Mar; 8(3):874-84. PubMed ID: 17315946
[TBL] [Abstract][Full Text] [Related]
40. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
Nam SM; Kim HS; Ahn WS; Park YS
Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
